TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01087554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase.
Study: NCT03487822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Path Pain
Description: The intervention examines the effects of PATH-Pain on emotion regulation to improve self-management of pain and pain-related disability in older adults with chronic pain, negative emotions, and cognitive impairment. This intervention consists of 8 weekly therapy sessions by a licensed clinician trained in Path Pain, 4 monthly boosters upon completion of therapy, and optional monthly group educational sessions.
Study: NCT03279250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing Hormone Analog
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study: NCT03581630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone/bupropion
Description: Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naltrexone/bupropion
Description: Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
Study: NCT02864836

Intervention type: PROCEDURE
Intervention: Samples collection
Description: 5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins

Intervention type: PROCEDURE
Intervention: Samples collection
Description: 5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins

Intervention type: PROCEDURE
Intervention: Samples collection
Description: 5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins
Study: NCT03792269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: intraperitoneal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study: NCT01359826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Milnacipran
Description: After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.
Study: NCT03162783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-102 Ophthalmic Solution (0.5%)
Description: ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
Study: NCT03968445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714-PET/MRI
Description: \[18F\]DPA-714-PET/MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714-PET/MRI
Description: \[18F\]DPA-714-PET/MRI
Study: NCT03718104

Intervention type: OTHER
Intervention: Pharmacokinetic analysis
Description: Pharmacokinetic analysis of maternal blood, maternal urine, cord blood, infant blood and urine for dyads in the naltrexone group at various time points in the pregnancy, at delivery, and 4 weeks postpartum.

Intervention type: OTHER
Intervention: Pharmacokinetic analysis
Description: Pharmacokinetic analysis of maternal blood, maternal urine, cord blood, infant blood and urine for dyads in the naltrexone group at various time points in the pregnancy, at delivery, and 4 weeks postpartum.
Study: NCT03162783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-102 Ophthalmic Solution (0.1%)
Description: ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
Study: NCT04634903

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy SSI
Description: Online, 30-minute self-administered program for youth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation SSI
Description: Online, 30-minute self-administered program for youth
Study: NCT03162783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-102 Ophthalmic Lipid Solution (0.5%)
Description: ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
Study: NCT03718104

Intervention type: OTHER
Intervention: Safety and Efficacy
Description: Examination of the safety and efficacy of naltrexone and comparison of outcomes with the buprenorphine/naloxone cohort. Outcomes examined will include: 1) maternal outcomes (relapse, retention in care, preterm labor); 2) fetal outcomes (growth, fetal anomalies, fetal distress, cortisol levels); and 3) infant outcomes (NAS, growth, neurodevelopment via NNNS exam at 4 weeks and Bayley exam at 12 months of age).

Intervention type: OTHER
Intervention: Safety and Efficacy
Description: Examination of the safety and efficacy of naltrexone and comparison of outcomes with the buprenorphine/naloxone cohort. Outcomes examined will include: 1) maternal outcomes (relapse, retention in care, preterm labor); 2) fetal outcomes (growth, fetal anomalies, fetal distress, cortisol levels); and 3) infant outcomes (NAS, growth, neurodevelopment via NNNS exam at 4 weeks and Bayley exam at 12 months of age).

Intervention type: GENETIC
Intervention: Genetic and epigenetic analysis
Description: Maternal blood and saliva DNA samples will be genotyped for single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) to look for associations with effectiveness of NTX and BPH. In addition, DNA methylation levels in the OPRM1 promoter within maternal and infant saliva and placenta at delivery and 4 weeks postpartum will be examined. Lastly, we will compare genome-wide DNA methylation levels at delivery and 4 weeks postpartum in mother-infant dyads.

Intervention type: GENETIC
Intervention: Genetic and epigenetic analysis
Description: Maternal blood and saliva DNA samples will be genotyped for single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) to look for associations with effectiveness of NTX and BPH. In addition, DNA methylation levels in the OPRM1 promoter within maternal and infant saliva and placenta at delivery and 4 weeks postpartum will be examined. Lastly, we will compare genome-wide DNA methylation levels at delivery and 4 weeks postpartum in mother-infant dyads.

Intervention type: GENETIC
Intervention: Genetic and epigenetic analysis
Description: Maternal blood and saliva DNA samples will be genotyped for single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) to look for associations with effectiveness of NTX and BPH. In addition, DNA methylation levels in the OPRM1 promoter within maternal and infant saliva and placenta at delivery and 4 weeks postpartum will be examined. Lastly, we will compare genome-wide DNA methylation levels at delivery and 4 weeks postpartum in mother-infant dyads.

Intervention type: OTHER
Intervention: Breast milk analysis
Description: Mothers in the naltrexone group will have their breast milk analyzed at 4 weeks post-delivery for naltrexone levels, with corresponding maternal and infant plasma levels.

Intervention type: OTHER
Intervention: Breast milk analysis
Description: Mothers in the naltrexone group will have their breast milk analyzed at 4 weeks post-delivery for naltrexone levels, with corresponding maternal and infant plasma levels.
Study: NCT04634903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Mindset SSI
Description: Online, 30-minute self-administered program for youth
Study: NCT03438422

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pollen extract
Description: 1 tablet a day
Study: NCT00664053

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHEA
Description: 50mg daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: 50mg daily for 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 2 sessions per week for 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: 2 sessions per week for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo supplement every day for 6 months
Study: NCT02916914

Intervention type: OTHER
Group type: OTHER
Intervention: Q2 feeding
Description: Infants are going to be fed every 2 hours
Study: NCT03438422

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pollen extract
Description: 1 tablet a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pollen extract
Description: 1 tablet a day
Study: NCT00664053

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement every day for 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobics
Description: Walking/chair aerobics program 2 sessions per week for 6 months

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aerobics
Description: Walking/chair aerobics program 2 sessions per week for 6 months
Study: NCT01139216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TU-100)
Description: Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TU-100)
Description: Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
Study: NCT05237830

Intervention type: PROCEDURE
Intervention: Use of Cell Salvage in revision of total hip arthroplasty
Description: The effective use of the cell saver was defined as the ability to re-transfuse at least 125 mL of re-suspended red blood cells with a hematocrit of 60 %.

Intervention type: PROCEDURE
Intervention: Use of Cell Salvage in revision of total hip arthroplasty
Description: The effective use of the cell saver was defined as the ability to re-transfuse at least 125 mL of re-suspended red blood cells with a hematocrit of 60 %.
Study: NCT03879187

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat, high-energy diet
Description: Participants consumed a diet that was high in fat and high in energy
Study: NCT03313713

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beta-glucans
Description: Placebo consumption at breakfast (3 g per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consumption at breakfast (3 g per day)
Study: NCT02472834

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid supplementation NephrAmine®
Description: Dialysis patients will be randomized to receive either 250 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing \~14 grams of essential amino acids during each dialysis session (3 times weekly for 8 weeks) or no treatment (standard-of-care)
Study: NCT03438422

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pollen extract
Description: 1 tablet a day
Study: NCT00520572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00960856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid 105 mg Tablet
Description: One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid 105 mg Tablet
Description: One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid 105 mg Tablet
Description: One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid 105 mg Tablet
Description: One 105 mg tablet administered after an overnight fast of at least 10 hours.
Study: NCT03347539

Intervention type: DEVICE
Intervention: Nexplaon
Description: This study is an exploratory study of user reasons for Nexplanon implant and removal, and NOT a study on the efficacy or safety of Nexplanon. Nexplanon has already been FDA approved and its efficacy and safety studied.
Study: NCT03664609

Intervention type: DEVICE
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation in patients with Parkinson Disease, Dystonia and Essential Tremor.

Intervention type: DEVICE
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation in patients with Parkinson Disease, Dystonia and Essential Tremor.

Intervention type: DEVICE
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation in patients with Parkinson Disease, Dystonia and Essential Tremor.
Study: NCT03383367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tempo Colo
Description: Reminder letter for people at high risk of colorectal cancer.
Study: NCT02748018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 670G and 770G Insulin Pump
Description: Medtronic 670G and 770G Hybrid Closed Loop Systems

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subject's Current Diabetes Therapy
Description: Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).
Study: NCT00737984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial sampling
Description: Endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
Study: NCT00943878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
Study: NCT01292395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Protein Intake
Description: Protein intakes within the current recommendation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Protein Intake
Description: Protein intakes within the current recommendation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Protein Intake
Description: Protein intakes within the current recommendation
Study: NCT01977534

Intervention type: DEVICE
Intervention: Absorb BVS
Description: The Absorb BVS System is a bioresorbable poly(L-lactide) (PLLA) scaffold with a drug and bioresorbable polymer coating \[formulation of everolimus in a bioresorbable poly(D,L-lactide) (PDLLA) coating\].
Study: NCT03415074

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protein restriction
Description: In both arms the dietary protein intake will be reduced. In the sLPD arm, the protein restriction is more severe and ketoanalogues of the essential aminoacids are offered.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protein restriction
Description: In both arms the dietary protein intake will be reduced. In the sLPD arm, the protein restriction is more severe and ketoanalogues of the essential aminoacids are offered.
Study: NCT02204540

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mock study intervention
Description: Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mock study intervention
Description: Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
Study: NCT01747330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancreatin
Description: Doses of Pancreatin \<2500 lipase u/kg/feed or \<4000 lipase U/g fat/intake or \<10000 lipase U/kg/day given orally are used
Study: NCT03330691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient-derived CD19- and CD22 specific CAR
Description: Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
Study: NCT04616118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Visit
Description: Participants randomized to this arm will receive usual care via telephone only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Visit
Description: Participants randomized to this arm will receive usual care via video call